Ocena postępowania diagnostycznego i terapeutycznego w ...

94. Siedlecki P, Zielenkiewicz P. Mammalian DNA methyltransferases. Acta Biochim Pol. 2006;
53: 245-56.
95. Best A, Matheson E, Minto L i wsp. Mismatch repair and the downstream target genes, PAX5
and Ikaros, in childhood acute lymphoblastic leukemia. Leuk Res. 2010; 34: 1098-102.
96. Chaganti RSK, Nanjangud G, Schmidt H, Teruya-Feldstein J. Recurring Chromosomal
Abnormalities in Non-Hodgkin’s lymphoma: biologic and clinical significance. Semin
Hematol. 2000;37: 396-411.
97. Mazur G i Haus O. Cytogenetyka i genetyka molekularna chłoniaków nieziarniczych. Pol
Arch Med Wewn. 2002; 108: 993-1000.
98. Nigro JM, Baker SJ, Preisinger AC i wsp.. Mutations in the p53 gene occur in diverse human
tumour types. Nature. 1989; 342: 705-08.
99. Martín-Subero JI, Odero MD, Hernandez R Amplification of IGH/MYC fusion in clinically
aggressive IGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes
Cancer. 2005; 43: 414-23.
100. Osuchowska Z, Kawiak J. Regulacja cyklu komórkowego. Post Biol Kom. 2002; 3: 465-88.
101. Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies
and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer.
1976;17: 47-56.
102. Ong ST, LeBeau MM. Chromosomal abnormalities and molecular genetics of non-Hodgkin
lymphoma. Semin Oncol. 1998; 25; 447-60.
103. Aplan PD. Causes of oncogenic chromosomal translocation. Trends in Genetics. 2006; 22:
46-55.
104. Pieńkowska-Grela B. Aplikacje kliniczne badań cytogenetycznych w złośliwych chłoniakach
nieziarniczych. Nowotwory. 2003; 53: 58-67.
105. Hecht J, Aster J. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000; 18: 37707-21.
106. Kramer M, Hermans J, Wijburg E i wsp. Clinical revelance of BCL-2, BCL-6 and MYC
rearrangements in diffuse large B-cell lymphoma. Blood. 1998; 92: 3152-62.
107. Abramson S i Shipp M. Advances in the biology and therapy of diffuse large B-cell
lymphoma: moving toward a molecularly targeted approach. Blood. 2005; 106: 1164-74
108. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell
lymphomas. Blood. 2003;101:1220-35.
109. Pasqualucci L, Bereschenko O, Niu H i wsp. Molecular pathogenesis of non-Hodgkin
lymphoma: the role of Bcl-6. Leuk Lymphoma. 2003; 44: 5-12.
110. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK).
Oncogene. 2001; 20: 5623-37.
111. Zamoyska R, Basson A, Filby A i wsp. The influence of the src-family kinases, Lck and Fyn,
on T cell differentiation, survival and activation. Immunol Rev 2003;191:107–18.
112. Cavé H, Suciu S, Preudhomme C i wsp. Clinical significance of HOX11L2 expression linked
to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell
malignancies: results of EORTC studies 58881 and 58951. Blood. 2004; 103: 442-50.
113. Riz I, Hawley RG. G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene
of T-cell acute lymphoblastic leukemia. Oncogene. 2005; 24: 5561-75.
114. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell
malignancies. Blood. 2000; 96: 808-22.
115. Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas.
Oncogene. 2001; 20: 5580-94.
116. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders, Hum
Pathol. 2007; 38: 1293-1304.
117. Wang Y, Liu X, Xing X i wsp. Variations of Epstein-Barr virus nuclear antigen 1 gene in
gastric carcinomas and nasopharyngeal carcinomas from Northern China. Virus Res.
2010;147: 258-64.
118. Pagano JS. Viruses and lymphomas. N Engl J Med. 2002; 347: 78-79.
119. Dobrzańska J, Sawczuk – Chabin J i Warzocha K. Rola wirusów w etiopatogenezie
chłoniaków nieziarniczych. Onkol Prak Klin. 2006; 2: 64-72.
141